7q4a

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (13:13, 1 February 2024) (edit) (undo)
 
(2 intermediate revisions not shown.)
Line 1: Line 1:
==Toxoplasma gondii PRP4K kinase domain (L715F) bound to altiratinib==
==Toxoplasma gondii PRP4K kinase domain (L715F) bound to altiratinib==
-
<StructureSection load='7q4a' size='340' side='right'caption='[[7q4a]]' scene=''>
+
<StructureSection load='7q4a' size='340' side='right'caption='[[7q4a]], [[Resolution|resolution]] 2.31&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7Q4A OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7Q4A FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[7q4a]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Toxoplasma_gondii Toxoplasma gondii]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7Q4A OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7Q4A FirstGlance]. <br>
-
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7q4a FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7q4a OCA], [https://pdbe.org/7q4a PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7q4a RCSB], [https://www.ebi.ac.uk/pdbsum/7q4a PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7q4a ProSAT]</span></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.31&#8491;</td></tr>
 +
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A9I:Altiratinib'>A9I</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene>, <scene name='pdbligand=SCN:THIOCYANATE+ION'>SCN</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7q4a FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7q4a OCA], [https://pdbe.org/7q4a PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7q4a RCSB], [https://www.ebi.ac.uk/pdbsum/7q4a PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7q4a ProSAT]</span></td></tr>
</table>
</table>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/S7UT92_TOXGG S7UT92_TOXGG]
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
The Apicomplexa comprise a large phylum of single-celled, obligate intracellular protozoa that include Toxoplasma gondii, Plasmodium, and Cryptosporidium spp., which infect humans and animals and cause severe parasitic diseases. Available therapeutics against these diseases are limited by suboptimal efficacy and frequent side effects, as well as the emergence and spread of resistance. We use a drug repurposing strategy and identify altiratinib, a compound originally developed to treat glioblastoma, as a promising drug candidate with broad spectrum activity against apicomplexans. Altiratinib is parasiticidal and blocks the development of intracellular zoites in the nanomolar range and with a high selectivity index when used against T. gondii. We have identified TgPRP4K of T. gondii as the primary target of altiratinib using genetic target deconvolution, which highlighted key residues within the kinase catalytic site that conferred drug resistance when mutated. We have further elucidated the molecular basis of the inhibitory mechanism and species selectivity of altiratinib for TgPRP4K and for its Plasmodium falciparum counterpart, PfCLK3. Our data identified structural features critical for binding of the other PfCLK3 inhibitor, TCMDC-135051. Consistent with the splicing control activity of this kinase family, we have shown that altiratinib can cause global disruption of splicing, primarily through intron retention in both T. gondii and P. falciparum. Thus, our data establish parasitic PRP4K/CLK3 as a potential pan-apicomplexan target whose repertoire of inhibitors can be expanded by the addition of altiratinib.
 +
 +
Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase.,Swale C, Bellini V, Bowler MW, Flore N, Brenier-Pinchart MP, Cannella D, Belmudes L, Mas C, Coute Y, Laurent F, Scherf A, Bougdour A, Hakimi MA Sci Transl Med. 2022 Aug 3;14(656):eabn3231. doi: 10.1126/scitranslmed.abn3231., Epub 2022 Aug 3. PMID:35921477<ref>PMID:35921477</ref>
 +
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 7q4a" style="background-color:#fffaf0;"></div>
 +
== References ==
 +
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Large Structures]]
[[Category: Large Structures]]
 +
[[Category: Toxoplasma gondii]]
[[Category: Bellini V]]
[[Category: Bellini V]]
[[Category: Bowler M]]
[[Category: Bowler M]]
[[Category: Swale C]]
[[Category: Swale C]]

Current revision

Toxoplasma gondii PRP4K kinase domain (L715F) bound to altiratinib

PDB ID 7q4a

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools